Traynor Capital Management Inc. Has $17.21 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Traynor Capital Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,608 shares of the biopharmaceutical company’s stock after acquiring an additional 1,129 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 1.0% of Traynor Capital Management Inc.’s holdings, making the stock its 19th biggest holding. Traynor Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $17,210,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Regeneron Pharmaceuticals by 9.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 62,569 shares of the biopharmaceutical company’s stock worth $35,181,000 after purchasing an additional 5,403 shares during the period. Bank of New York Mellon Corp boosted its stake in Regeneron Pharmaceuticals by 2.3% in the third quarter. Bank of New York Mellon Corp now owns 671,630 shares of the biopharmaceutical company’s stock valued at $377,638,000 after acquiring an additional 15,006 shares during the last quarter. Ballentine Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 10.9% during the 3rd quarter. Ballentine Partners LLC now owns 1,066 shares of the biopharmaceutical company’s stock valued at $599,000 after acquiring an additional 105 shares during the last quarter. Valeo Financial Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 3.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 1,866 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 69 shares during the last quarter. Finally, J. Safra Sarasin Holding AG lifted its stake in shares of Regeneron Pharmaceuticals by 309.8% in the 3rd quarter. J. Safra Sarasin Holding AG now owns 2,303 shares of the biopharmaceutical company’s stock valued at $1,295,000 after purchasing an additional 1,741 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on REGN shares. Truist Financial upped their price objective on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $784.77.

Regeneron Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ:REGN opened at $751.13 on Thursday. The firm has a market cap of $78.94 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 2.01 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company’s fifty day simple moving average is $758.43 and its 200 day simple moving average is $647.96. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.46 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.